Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael Megna sold 11,280 shares of the company's stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $98.54, for a total value of $1,111,531.20. Following the completion of the sale, the chief accounting officer owned 12,697 shares of the company's stock, valued at $1,251,162.38. This trade represents a 47.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Stock Performance
NASDAQ:KNSA opened at $96.28 on Friday. Kiniksa Pharmaceuticals International, plc has a one year low of $37.02 and a one year high of $99.31. The stock has a market cap of $7.56 billion, a PE ratio of 74.06 and a beta of 0.07. The stock has a 50 day moving average price of $81.86 and a 200 day moving average price of $62.44.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. As a group, analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company's stock valued at $35,436,000 after acquiring an additional 506,576 shares during the period. Rubric Capital Management LP lifted its holdings in shares of Kiniksa Pharmaceuticals International by 12.7% in the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company's stock worth $180,562,000 after acquiring an additional 421,347 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Kiniksa Pharmaceuticals International by 213.5% during the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company's stock worth $23,197,000 after purchasing an additional 327,595 shares in the last quarter. Spruce Street Capital LP boosted its position in shares of Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company's stock worth $36,645,000 after buying an additional 326,081 shares during the period. Finally, Pictet Asset Management Holding SA boosted its position in shares of Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company's stock worth $64,182,000 after buying an additional 251,578 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
KNSA has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price target on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. The Goldman Sachs Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a "buy" rating in a report on Wednesday, October 28th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Wednesday, October 28th. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 30th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $100.57.
Get Our Latest Stock Analysis on Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Company Profile
(
Get Free Report)
Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa's marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
